Twist Bioscience Corp

TWST remains in a Stage 2 advancing uptrend anchored by higher highs/lows and rising EMAs, but a Blow-Off Top exhaustion at fresh highs amid extreme overbought readings has produced a near-term rejection candle. Short-term timing is unfavorable for new long entries, so execution is deferred. We will stalk for a corrective pullback into the rising 9/20 EMA support zone and look for clear acceptance before participating.

• ↑Q2 2026 revenue +19.3% YoY to $110.7 M, DNA solutions +28%.
• ↑Gross margin expanded to 51.6% with adjusted EBITDA breakeven expected in Q4.
• ↓Negative earnings yield and weak profitability metrics question ROI sustainability.